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Background: Transfusion-transmitted infections are a major problem associated with blood transfusion. The aim of
this study was to determine prevalence and trends of HBV, HCV and HIV in blood donors in Argentina.
Methods: A retrospective study was carried out in blood donors of 27 transfusion centers covering the whole country
over a period of eight years (2004-2011). Serologic screening assays for HBsAg, anti-HBc, anti-HCV, and anti-HIV were
performed in all centers and nucleic acid amplification testing (NAT) was performed in 2 out of the 27 centers.
Results: The 2,595,852 samples tested nationwide from 2004 to 2011 showed that the prevalence of HBsAg decreased
from 0.336% to 0.198% (p < 0.0001), that of anti-HBc from 2.391% to 2.007% (p < 0.0001), that of anti-HCV from 0.721%
to 0.460%, (p < 0.0001) and that of anti-HIV from 0.208% to 0.200 (p = 0.075). The prevalence of HBV, HCV and HIV was
unevenly distributed among the different regions of the country. Two out of 74,838 screening- negative samples
were positive in NAT assays (1 HIV-RNA and 1 HCV-RNA); moreover, HBV-DNA, HCV-RNA and HIV-RNA were detected
in 60.29, 24.54 and 66.67% of screening-positive samples of the corresponding assays. As regards donors age,
positive HBV-DNA and HCV-RNA donors were significantly older than healthy donors (46.6, 50.5 and 39.5 y
respectively, p < 0.001).
Conclusions: Argentina has a low prevalence of HBsAg, anti-HCV and anti-HIV in blood donors, with a decreasing
trend for HBsAg, anti-HBc and anti-HCV but not for anti-HIV over the last 8 years. The uneven distribution of
transfusion-transmitted infections prevalence among the different regions of the country highlights the need
to implement regional awareness campaigns and prevention. The discrepancy between samples testing positive for
screening assays and negative for NAT assays highlights the problem of blood donors who test repeatedly reactive in
screening assays but are not confirmed as positive upon further testing. The uneven distribution of age between
healthy donors and NAT-positive donors could be related to changes in risks of these pathogens in the general
population and might be attributed to a longer exposure to transmission risk factors in elderly people.
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Hepatitis B (HBV), hepatitis C (HCV) and human im-
munodeficiency (HIV) viruses, the three most important
agents responsible for transfusion-transmitted infections
(TTIs), are a global public health problem and still a large
health care burden globally. It is currently estimated that
about 350 million people worldwide are chronically in-
fected with HBV, 170 million with HCV and 38 million
HIV [1-5].
The evaluation of the prevalence and distribution of
HBV, HCV and HIV is important for the planning of
preventive measures and particularly, in the case of HBV,
for the development of vaccination programs. The preva-
lence rates across the world are difficult to calculate given
the asymptomatic and often latent nature of these dis-
eases prior to clinical presentation [6,7]. The ideal condi-
tion to carry out a seroprevalence study is to sample the
general population; however, this is not always feasible.
Because of the low prevalence of these infections in the
general population, their determination is cumbersome
because it would imply large sample sizes. For this reason,
although blood donors may not reflect the general
population, most of the studies are performed in this
group because results could be invaluable data to bet-
ter understand the epidemiology of these diseases in
the community [8-11].
In addition, the laboratory procedures and brands of
reagents used in the different centers may differ in sensi-
tivity and specificity; comparisons between them are not
straightforward. In spite of these limitations, the infor-
mation found is helpful, because in Argentina, there is a
paucity of current epidemiological studies including an
appropriate sampling of the general population [12].
In the last years, several studies have estimated the
epidemiological burden of HBV, HCV and HIV infection
in Argentina. Nonetheless, most of the data are outdated
[13,14] or come from regional studies focused on small
communities with an unrepresentative number of cases
[15-18]. There are also studies limited to vulnerable pop-
ulations or coinfected patients [19-22]. Therefore, there
is a paucity of information about the current burden of
HBV, HCV and HIV in Argentina.
In Argentina, altruistic repeat donors are the exception
rather than the rule and most blood comes from new
donors; feature that did not change significantly during
the period in which the study was conducted [23]. This
should be taken into consideration, since the prevalence
of positive serologic tests for infectious diseases in these
donors is higher than that among repeat volunteers, who
are subjected to periodic screening [24,25].
A better understanding of the prevalence of TTIs can
help medical communities and government agencies man-
age the disease burden and develop strategies in light of
the emergence of several potent antiviral therapies. Thepresent study should help to increase awareness of TTIs
in the region.
In the present retrospective study, we evaluated the
seroprevalence of HBV, HCV and HIV among blood do-
nors in Argentina from 2004 to 2011. We also deter-
mined the trend of these infections and compared the
prevalence in the different regions of the country.
Methods
Population
Blood donor records covering the period between 2004
and 2011 were analyzed. Data were collected from 27
transfusion centers throughout the country, 24 of which
were public and 3 were private. In the course of the study,
most (~90%) blood donors were volunteers or relatives or
friends of the recipients, whereas the remaining ones were
repeat volunteers, periodically subjected to screening.
Potential donors undergo a questionnaire and a phys-
ical examination performed by trained physicians. Those
who are apparently healthy, are between 18-65 years old
and weigh above 45 kg are qualified for donation.
The data were analyzed considering seven geographic
regions: northwest (NW), northeast (NE), West, South,
Center, Buenos Aires city (CABA) public and private cen-
ters, as well as the provinces that make up each region.
In addition, age and gender of 744 healthy donors ran-
domly selected, from 2 centers where NAT assays are
routinely performed, were recorded to compare the epi-
demiological features of NAT positive donors with those
of non-reactive. The size of the healthy donor’s popula-
tion was estimated by considering a confidence level of
95% and 1% of accuracy.
Serologic assays
Serum samples were tested using third and fourth gener-
ation enzyme immune assays (EIAs) following the manu-
facturer’s instructions, for the presence of hepatitis B
surface antigen (HBsAg), anti-Core antibody (anti-HBc),
antibodies for hepatitis C and antibodies for HIV. The
different centers used several methodologies, even in the
same center, over the study period.
Trademarks used were, for HBsAg: PRISM HBsAg,
ARCHITECT HBsAg, AxSYM HBsAg (Abbott Diagnos-
tics, IL, USA), Murex HBsAg version 3 (Abbott Diagnos-
tics, IL, USA) and Hepanostika HBsAg Ultra (Organon
Teknika, Boxtel, The Netherlands). For anti-HBc: PRISM
HBcore, ARCHITECT CORE (Abbott Diagnostics, IL, USA),
Hepanostika anti-HBc Uniform (Organon Teknika, Boxtel,
The Netherlands), Anti-HBc (Radim, Pomezia, Italy), Enzyg-
nost Anti HBc (Dade Behring, IL, USA) and anti-HBc
(Dia.Pro Diagnostic BioProbes, Milan, Italy). For anti-
HCV: PRISM HCV, ARCHITECT anti-HCV (Abbott
Diagnostics, IL, USA), HCV Version 3.0 (Ortho Clinical
Diagnostics, NJ, USA), Bioelisa HCV 4.0 (Biokit, Lexington
Table 1 Prevalence of HBsAg, anti-HBc, anti-HCV and
anti-HIV in 2011 by region and province
Donors Prevalence (%)
HBsAg Anti-HBc Anti-HCV Anti-HIV
NW 54,138 0.451 5.221 0.660 0.131
Jujuy 9,740 0.671 7.378 0.385 0.147
Salta 16,229 0.725 10.136 0.678 0.285
Tucumán 14,746 0.206 1.929 0.857 0.053
Catamarca 2,874 0.319 2.252 0.457 0.012
La Rioja 3,832 0.272 2.293 1.015 0.330
Santiago del Estero 6,717 0.467 1.875 0.344 0.113
NE 45,899 0.291 3.163 0.335 0.124
Formosa 11,512 0.231 3.810 0.458 0.105
Chaco 12,041 0.125 1.473 0.297 0.115
Corrientes 12,821 0.176 1.153 0.295 0.089
Misiones 9,525 0.656 7.039 0.344 0.197
South 23,344 0.223 1.570 0.446 0.247
Neuquén 5,178 0.226 1.997 0.562 0.376
Rio Negro 5,503 0.250 0.717 0.276 0.130
Chubut 6,717 0.183 1.424 0.239 0.143
Santa Cruz 4,018 0.249 1.768 0.693 0.338
Tierra del Fuego 1,928 0.177 1.629 0.457 0.129
West 25,600 0.280 1.702 0.434 0.131
Mendoza 17,332 0.357 2.018 0.530 0.180
San Juan 4,971 0.128 1.192 0.117 0.022
San Luis 3,297 0.097 0.807 0.349 0.026
Center 320,595 0.151 1.466 0.436 0.200
Córdoba 57,360 0.155 1.512 0.456 0.221
La Pampa 4,250 0.246 0.791 0.499 0.193
Buenos Aires 209,281 0.112 1.313 0.462 0.219
Entre Ríos 16,483 0.132 1.259 0.195 0.063
Santa Fe 33,221 0.221 2.262 0.349 0.105
CABA (public) 60,807 0.181 2.077 0.641 0.308
CABA (private) 43,135 0.090 1.085 0.287 0.104
TOTAL 530,383 0.198 2.007 0.460 0.190
CABA: Buenos Aires city.
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Milan, Italy) and Murex anti-HCV 4.0 (Murex Biotech
Ltd., Dartford, United Kingdom) and for anti-HIV: PRISM
HIV O Plus, ARCHITECT HIV Ag/Ab Combo, AxSYM
HIV Ag-Ab Combination (Abbott Diagnostics, IL, USA),
Murex HIV Ag-Ab Combination (Murex Biotech Ltd.,
Dartford, United Kingdom), HIV Ab&Ag 4th Gen (DIA.
PRO Diagnostic, Bioprobes srl, Milan, Italy), VIDAS HIV
Duo Ultra (Biomerieux, Marcy l’Etoile, France), GS HIV-1/
HIV-2 PLUS O (Ortho Clinical Diagnostics, NJ, USA).
Nucleic acid amplification testing (NAT) assays
The HBV, HCV and HIV nucleic acids were routinely
tested in two of the 27 centers using Cobas Taqscreen
MPX test (ROCHE) and Procleix Ultrio test (Chiron),
following the manufacturer’s instructions. Positive sam-
ples were later analyzed with Procleix HIV-1, HCV and
HBV Discriminatory assays or Cobas TaqScreen MPX
Test, v2.0 to determine which viral nucleic acid or com-
bination of nucleic acids was causing the reaction.
Statistical analysis
Results were expressed as mean ± SD. Fisher’s two-tailed
exact test and the corrected X2 test were used to com-
pare qualitative data. ANOVA and non-parametric test
(Mann-Whitney U and Kruskal-Wallis H) were used to
compare quantitative variables. The data were entered
into a computer and analyzed using Statistical Package
for Social Sciences (SPSS, Chicago, IL, USA), version
16.0. Significance was set at a value of less than 0.05.
Ethical aspects
This study was approved by the Ethics Committee of the
School of Pharmacy and Biochemistry, Buenos Aires
University (EXPTE. N° 732575). Interviews and blood
sample collection were conducted after written consent
forms had been signed. The study was performed in ac-
cordance with provisions of the Declaration of Helsinki
and Good Clinical Practice guidelines.
Results
Population
During the 8-year study, the number of blood donors
progressively increased from 352,771 in 2004 to 573,518
in 2011. The sampling in 2011 represented 1.38% of the
country population, (41,660,417 inhabitants) and ranged
between 0.73 and 2.10% in the different regions studied.
HBV prevalence
In 2011, the nationwide prevalence of HBsAg was 0.198 ±
0.179% (0.090-0.725%), being unevenly distributed in the
different regions of the country (Table 1).
The highest prevalence rate was observed in the NW re-
gion (0.451%); particularly, among the provinces belongingto this region, Salta (0.725%) and Jujuy (0.671%) showed
prevalence rates higher than the other provinces of this
region (Tucuman 0.206%, Catamarca 0.319%, La Rioja
0.272% and Santiago del Estero 0.467%).
The other regions showed similar prevalence rates, ran-
ging from 0.090 to 0.291%. However, although the rate in
the NE region was within the average (0.291%), the preva-
lence in the province of Misiones (0.656%), belonging to
this region, was significantly higher, only comparable to
that in Salta and Jujuy. Finally, the prevalence of HBsAg
was significantly different between CABA public centers
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ively, p < 0.001).
The anti-HBc prevalence broadly followed the HBsAg
rates, being the national prevalence 2.007 ± 2.308% (range
0.717-10.136%). The provinces with higher HBsAg rates
(Salta, Jujuy and Misiones) showed high prevalence rates
of anti-HBc (> 7.0%). The average ratio of anti-HBc/HBsAg
was 9.87 ± 2.29, ranging from 6.074 to 12.00 in the differ-
ent regions.
Along the study period, we found a slight and signifi-
cant decrease at nationwide level for HBsAg prevalence
from 0.356% in 2004 to 0.198% in 2011 (p < 0.0001) and
for anti-HBc prevalence from 2.391% in 2004 to 2.007%
in 2011 (p < 0.0001) (Table 2). This pattern was observed
in four out of the seven regions studied (NW, West,
Center and CABA public centers) whereas it remained
steady in the other three regions (NE, South and CABA
private centers) (Figure 1).
HCV prevalence
In 2011, the nationwide prevalence of anti-HCV was
0.460 ± 0.207% (0.117-1.015%), being significantly higher
in the NW region (0.660%) and CABA public centers
(0.641%) than in the other regions (Table 1). In particu-
lar, among the provinces belonging to the NW region,
Salta (0.678%), Tucumán (0.857%) and La Rioja (1.015%)
showed significantly higher prevalence rates than the
other provinces of this region. The other regions showed
similar prevalence rates ranging from 0.287 to 0.446%.
Similarly to that observed for HBsAg, the prevalence of
anti-HCV in the CABA public centers was significantly
different from that in the CABA private centers, being
0.641% and 0.287% respectively (p < 0.001).
In the longitudinal study between 2004 and 2011, the
nationwide level of anti-HCV showed a significant de-
crease from 0.721% in 2004 to 0.460% in 2011 (p < 0.0001)
(Table 2). This pattern was observed in five out of seven
regions studied (NE, West, Center, CABA public and
CABA private); whereas it remained unchanged in the
other two regions (NW and South) (Figure 1).Table 2 Comparison of prevalence rates between 2004 and 2
HBsAg Anti-HBc
Region 2004 2011 p 2004 2011
NW 0.660 0.451 0.001 4.623 5.221 0.
NE 0.371 0.291 0.054 2.809 3.163 0.
South 0.254 0.223 0.560 1.895 1.570 0.
West 0.419 0.280 0.009 1.728 1.702 0
Center 0.416 0.151 <0.001 2.110 1.466 <0
CABA public 0.282 0.181 <0.001 2.946 2.077 <0
CABA private 0.090 0.090 1.000 1.945 1.085 <0
TOTAL 0.336 0.198 <0.001 2.391 2.007 <0HIV prevalence
In 2011, the nationwide prevalence of anti-HIV was 0.190 ±
0.103% (0.012-0.376%). Overall, the prevalence by regions
ranged from 0.104 to 0.247% except in CABA public cen-
ters (0.308%), where it was significantly higher than in the
other regions (Table 1). In some provinces as, La Rioja
(0.330%), Neuquén (0.376%) and Santa Cruz (0.338%) the
prevalence was above the average.
The prevalence of anti-HIV in the public centers of
CABA was significantly different from that in the private
centers of CABA, being 0.308% and 0.104% respectively
(p < 0.001).
Along the study period, the nationwide prevalence of
anti-HIV between 2004 and 2011 was unchanged (0.208
to 0.190%; p = 0.075) (Table 2). It only showed a signifi-
cant decrease in the Center (0.247 to 0.200%; p < 0.001)
and a significant increase in the South (0.075 to 0.247%;
p < 0.001) (Figure 1).
Nucleic acid amplification testing (NAT)
During 2010 and 2011, 75,200 donors were routinely tested
by NAT assays in two private centers CABA; 74,838 of
these were negative in serologic assays and 362 were posi-
tive in serology assays for any of transfusion-transmissible
agents. Two out of 74,838 screening- negative samples
were positive in NAT assays: one for HCV-RNA and the
other for HIV-RNA.
On the other hand, when screening -positive samples
were analyzed, HBV-DNA was detected in 41 out of 68
(60.29%) HBsAg-positive samples (Figure 2). The rate of
HBV-DNA was significantly higher in those samples also
reactive for anti-HBc (94.12%, 32 of 34) than in samples
with HBsAg alone (24.47%, 9 of 34) (p = 8.8e-9). While,
HCV-ARN was detected in 53 out of 216 anti-HCv posi-
tive samples (24.54%) and HIV-RNA in 52 out of 78 anti-
HIV positive samples (66.67%).
Finally, when comparing healthy donors and NAT-
positive samples by age, HBV-DNA positive donors were
significantly older than healthy donors (46.6 ± 14.8 vs 39.5 ±
11.7, p = 0.001) (Table 3). Most of the positive samples011 in the different regions for each serological marker
Anti-HCV Anti-HIV
p 2004 2011 p 2004 2011 p
004 0.618 0.660 0.572 0.112 0.131 0.578
004 0.509 0.335 <0.001 0.091 0.124 0.164
025 0.513 0.446 0.351 0.075 0.247 <0.001
.823 0.659 0.434 <0.001 0.080 0.131 0.068
.001 0.753 0.436 <0.001 0.247 0.200 <0.001
.001 0.945 0.641 <0.001 0.292 0.308 0.617
.001 0.507 0.287 <0.001 0.150 0.104 0.070
.001 0.721 0.460 <0.001 0.208 0.190 0.066
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Figure 1 Trend in prevalence of HBsAg, anti-HBc, anti-HCV and anti-HIV in blood donors from 2004 to 2011. CABA: Buenos Aires city.
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19.3% of healthy donors were in this age range (Figure 3).
As regards HCV-RNA positive donors, age distribution was
also significantly higher (50.5 ± 14.3, p < 0.0001) than that
of healthy donors (Table 3); particularly, there was a clear
cut of positivity frequency between donors younger than
40 years (17.0%) and those over 40 years (83.0%) (Figure 3).
Finally, the age distribution of HIV-RNA-positive donors
was not significantly different from that of healthy donors0,0
0,1
0,2
0,3
0,4
HBsAg HBsAg + anti -HBc
Po
sit
yv
ity
 ra
te
 (%
)
EIA positive
Figure 2 Positivity rates in screening test and NAT assays. In the years
NAT assays in two CABA transfusion centers. White bars: screening-positive(37.1 ± 9.7, p = 0.168). However, the highest incidence was
observed in the 30-40 age range (40.4%) (Figure 3).
Discussion
In this study, we characterized the prevalence and trend
of HBsAg, anti-HBc, anti-HCV and anti-HIV in blood
donors in Argentina between 2004 and 2011.
Although most studies on the seroprevalence of TTIs
come from blood centers, these data are biased. Data mayanti -HCV anti -HIV
NAT positive
2010 and 2011 75,200 samples were analyzed by screening test and
test, gray bars: NAT-positive test.
Table 3 Comparison of age and gender between healthy
donors and NAT positive donors
Healthy
donors
HBV-DNA Anti-HBc HCV-RNA HIV-RNA
n 744 41 254 53 52
Ratio m:f 1.9 3.6 3.4 2.1 9.4*
Mean
age (y)
39.5 46.6* 47.0* 50.5** 37.1
SD (y) 11.7 14.8 14.3 14.4 9.7
*p < 0.001, **p < 0.0001.
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are preselected based on a questionnaire and a physical
exam and blood is drawn only from those who appear at
low risk of having blood-borne pathogens- or overesti-
mated -given that, as in most studies performed in blood
banks, positive screening tests are not confirmed and have
a variable percentage of false positives.
Nevertheless, by comparing several studies, Petrovic
showed that the ratio of prevalence between general0
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Figure 3 Frequency of positive HBV-DNA, HCV-RNA and HIV-RNA by
dashed line: healthy donors.population and blood donors ranges from 1.17 to 1.70 for
HBsAg and from 1.25 to 3.00 for anti-HCV [26]. More-
over, in a study conducted by Karaosmanoglu, a ratio of
1.89 was observed when comparing the prevalence of
HBsAg among blood donors and healthy people who
required a premarital screening [27]; whereas in a study
performed by Baha, where HBV and HCV prevalence in
general population and blood donors was compared, a ra-
tio of 2.55 and 1.89 for HBV and HCV, was observed [28].
Therefore, although the seroprevalence determined from
blood donors may not reflect that of the general popula-
tion, it provides a better understanding of the epidemi-
ology of these diseases in the community [29].
Overall, our results show that the current prevalence
of HBsAg, anti-HCV and anti-HIV in blood donors in
Argentina is relatively low. The HBsAg and anti-HCV
prevalence was unevenly distributed across the country,
both between and within regions. This suggests the need
to implement regional awareness campaigns and preven-
tion according to the severity of the problem, to reduce40
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age. Gray areas: NAT-positive female; white areas: NAT-positive male;
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tween anti-HBc/HBsAg indicates a chronicity rate below
10%, suggesting that the transmission of HBV in Argentina
occurs mostly during adulthood.
The common finding that the prevalence of serologic
markers of infection was higher in donors from the public
blood banks suggests, as previously stated by Schmuñis
[18], a difference in the socioeconomic status of the do-
nors, which is usually associated with an increased condi-
tion of vulnerability.
Although blood bank data may underestimate the true
prevalence, it is likely that the trend in the donors pro-
vides a conservative estimate of the trend in the general
population [30]. The average rates of HBsAg and anti-
HCV in most of the regions and nationwide decreased
significantly over time between 2004 and 2011. These re-
sults are in agreement with the trend observed in our
country by Schmuñis in the 1990s [18] and may be the
consequence of increased public consciousness and ef-
fective use of preventive measures, particularly in HBV
because of the implementation of vaccination plans. How-
ever, it could also be partly due to the improvement in the
specificity of diagnostic tests during this period. On the
other hand, anti-HIV prevalence did not change signifi-
cantly over the study period.
Although HBV, HCV and HIV share the transmission
routes, and even though the sexual transmission of HCV
is not very efficient, the different trends observed in the
last years between HBV and HCV compared with HIV
prevalence could be due to prevention and awareness
measures mainly associated with those factors that are
more preponderant for HBV and HCV infections, such
as IVDU or socioeconomic status.
NAT assays are usually done to reduce the window period
and consequently reduce the risk of TTIs; nonetheless,
they are also useful to assess the specificity of serologic
screening tests. An increase in screening test sensitivity of
TTIs is highly desirable to ensure recipient safety. How-
ever, in populations with a low prevalence rate, the posi-
tive predictive value is relatively poor [31-33].
Viral nucleic acids were not detectable in a significant
number of reactive samples in screening assays (Figure 2).
This suggests that, regardless of the sensitivity of NAT
assays, most of these samples were false positive. Actually,
a major problem facing blood banks today is the loss of do-
nors who test repeatedly reactive in screening enzyme im-
munoassays but are not confirmed as positive upon further
testing [34].
As regards HBV, many authors have observed low speci-
ficity for total anti-HBc tests when using enzyme immuno-
assays [32,35,36]. However, the use of this immunoassay as
additional marker significantly increased the positive pre-
dictive value of the identification of truly HBV-infected in-
dividuals. In the case of HCV, it is estimated that between15 and 25% of infections are self-limited, a percentage that
varies depending on the HCV genotype. Therefore, the
false positive rate, although high, is probably lower than
75.46%. Considering 15 to 25% of self-limited infections,
the false positive rate would range from 67.28 to 71.13%.
Similar results have been observed in previous studies
by comparing EIA screening assays with confirmatory as-
says [37-39]. Finally, the test for HIV showed the highest
specificity when compared with NAT assays. These
results are consistent with those obtained in previous
studies [32,33,40].
Overall, our results suggest that the true prevalence in
blood donors, particularly for HBV and HCV, is signifi-
cantly lower than that determined by considering the
screening tests.
The uneven distribution of age between healthy donors
and NAT-positive donors could be related to changes in
risks of these pathogens in the general population. Teen-
age children and young adults in the 1960s and 1970s
(who were over 40 years old between 2010 and 2012)
might have received transfusions or medical procedures
with non-disposable needles and thus might have become
infected with HCV. The increase in HIV prevalence
among donors between 30 and 40 years of age since 2000
could reflect the change in perception among the public
about HIV threat and could have therefore led to a more
relaxed control of HIV transmission. For example, some
people might have mistakenly believed that available treat-
ment for HIV infection is effective and thus might have
engaged in more risky behavior, which could have resulted
in the recent increase in new infections among men who
have sex with men in certain areas [41,42]. These results
are consistent with those obtained in previous studies
[25,28,43].
From our results, it is evident that the status of the blood
supply in Argentina improved steadily from 2004 through
2011 and follows the trend described by Schmuñis from
1995 to 1997 [18].
Despite the limitations of the data discussed above, it
is clear from the analysis that there is a need to establish
a continued monitoring system to detect pitfalls that
need remedy and to gain support to strengthen blood
banking activities and assess the level and quality of
screening for infectious diseases in the blood supply.
Conclusions
The present study provides an updated description of
the prevalence and trends of HBV, HCV and HIV in
blood banks in Argentina. The analysis by region and
province; allowed to understand the different prevalence
and trend scenarios of these transfusion-transmitted
agents throughout the country; highlighting the need to
implement regional awareness campaigns and prevention
according to the severity of the problem. The longitudinal
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http://www.biomedcentral.com/1471-2334/14/218analysis of the data allowed to determine the trend of
transfusion-transmitted infections; emphasizing an overall
decrease in the prevalence of HBV and HCV infections in
the last years. Moreover, the comparative analysis of EIA
and NAT assays, conducted in two centers, allowed asses-
sing, for the first time in our country, -the impact of imple-
menting this methodology in the routine screening, -the
specificity of screening assays and -the usefulness of in-
cluding the antiHBc test in the screening.
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